Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRNCM-1
- Development stage
- Preclinical
- Lead developer
- Lineage Cell Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
GRNCM-1 (also known as AST-CM1) is a cell therapy product composed of human embryonic stem cell (hESC)-derived cardiomyocytes. Originally developed by Geron Corporation and subsequently acquired by Asterias Biotherapeutics (now Lineage Cell Therapeutics), the therapy is intended for the treatment of heart diseases, particularly myocardial infarction and chronic heart failure. The therapeutic approach involves the direct injection of these functional cardiomyocytes into the damaged myocardium to replace lost or necrotic heart muscle cells, thereby improving cardiac contractility and overall heart function. While the project was listed as "Pending" in certain databases, it represents a foundational effort in regenerative medicine for cardiovascular repair.
- Other names
- hESC-derived cardiomyocyteshuman embryonic stem cell-derived cardiomyocytes
Beyond the preview
Go deeper on GRNCM-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRNCM-1.